Last Updated: 18/06/2024
Understanding parasite ubiquitination to generate novel antimalarials
Objectives
This project proposes a new method of drug treatment that can be adapted to specifically target parasites. It will initially identify and then activate parasite protein complexes known the E3 ubiquitin ligases, using drugs known as PROTACs, to ultimately degrade key parasite proteins.
Principal Institution
Walter and Eliza Hall Institute of Medical Research (WEHI), Australia
Principal Investigators / Focal Persons
Rationale and Abstract
Malaria remains the most serious and widespread parasitic disease in humans. As parasites show increasing resistance to the frontline treatments, we need potent antimalarial drugs with new modes of action.
External reference
Thematic Categories
Date
Jan 2020 — Dec 2024
Total Project Funding
$444,693
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant ID: 1177431
AUD 639,750
Project Site
Related Resources
